2023-05-10 07:25:24 ET
- PolyPid press release ( NASDAQ: PYPD ): Q1 GAAP EPS of $0.28 beats by $0.56 .
- As of March 31, 2023, the Company had cash and cash equivalents and deposits in the amount of $13.4 million,
- Research and development (R&D) expenses for the three months ended March 31, 2023, were $3.8 million, compared to $8.7 million in the same three-month period of 2022. The decrease in R&D expenses resulted primarily from the completion of the SHIELD I Phase 3 clinical trial.
- General and administrative (G&A) expenses for the three months ended March 31, 2023, were $1.6 million, compared to $2.5 million for the same period of 2022.
- Marketing and business development expenses for the three months ended March 31, 2023, were $0.4 million, compared to $0.8 million for the same period of 2022.
For further details see:
PolyPid GAAP EPS of $0.28 beats by $0.56